To estimate the potential impact of ICs on the antitumor T-cell responses in CRC, we analyzed, using flow cytometry, the ex vivo expression of five of them—namely PD-1, TIGIT, Tim-3, Lag3 and NKG2A—in CD3+ TILs, present in 40 dissociated CRC tumors (three cohorts, see Table 1), including 34 MSS and 6 MSI tumors, with the gating strategy shown in Figure S1A. This evidence concerns the gene HAVCR2 and colorectal carcinoma.